TABLE 3

CCM compared with IENF pathology in diabetic patients stratified according to severity of small fiber dysfunction

Control subjectsNoneMildModerateSevere
CNFD (no/mm2)*43.20 ± 5.0524.88 ± 2.4122.13 ± 3.0526.71 ± 4.7616.20 ± 1.64
IENFD (no/mm)*11.21 ± 0.847.22 ± 1.045.75 ± 0.855.12 ± 1.163.20 ± 0.77,
CNBD (no/mm2)*27.39 ± 3.316.87 ± 1.608.33 ± 2.079.26 ± 2.634.63 ± 1.49
IENFBD (no/mm2)*139.66 ± 23.4244.99 ± 8.9334.47 ± 9.5240.38 ± 15.9827.19 ± 6.56
CNFL (mm/mm2)6.14 ± 1.223.97 ± 0.803.48 ± 0.474.61 ± 0.643.36 ± 0.44
IENFL (μm)42.10 ± 4.3132.64 ± 2.7830.21 ± 3.9824.96 ± 4.4734.84 ± 8.39
  • Data are means ± SE for patients were stratified according to the severity of small fiber dysfunction which included CDT, HP-VAS 0.5, HP-VAS 5.0, DB-HRV. Statistically significant difference using ANOVA:

  • * P < 0.001.

  • Post hoc results significantly different from control subjects.

  • Post hoc results significantly different from patients with no neuropathy.